Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mazighi Mikaël, Lambert Jerome, Gory Benjamin, Seners Pierre, Calvière Lionel, Cho Tae Hee, Aghetti Agnès, Pasi Marco, Boulouis Gregoire, Lapergue Bertrand, Consoli Arturo, Turc Guillaume, Rouchaud Aymeric, Wolff Valerie, Pop Raoul, Suissa Laurent, Richard Sébastien, Cordonnier Charlotte, Arquizan Caroline, Costalat Vincent, Guedon Alexis, Cognard Christophe, Mameri Lakhdar, Escalard Simon, Redjem Hocine, Smajda Stanislas, Robichon Erwan, Al Raaisi Amira, Boisseau William, Blanc Raphaël, Maier Benjamin, Boursin Perrine, Dubus Estelle, Desilles Jean-Philippe, Piotin Michel, Rigon Matthieu Resche, Olivot Jean-Marc
Аннотация
METHODS: GREEN is a multicenter, randomized, double blind, placebo controlled study. Participants presenting with AIS and a large vessel occlusion of the anterior circulation (intracranial internal carotid artery or middle cerebral artery, or both), with symptoms onset within 24 hours, will be randomized to one of two groups: intravenous glenzocimab 1000 mg with standard of care (SoC-EVT±IVT) or SoC (EVT±IVT) plus placebo. The main primary efficacy endpoint is functional outcome (assessed by the modified Rankin Scale score) at 90 days.
CONCLUSION: This is the first randomized trial evaluating the efficacy of glenzocimab with EVT. This prospective trial aims to determine whether glenzocimab with EVT improves functional outcome.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05559398.